Capital International Sarl Grows Stock Holdings in Pfizer Inc. $PFE

Capital International Sarl boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 418,615 shares of the biopharmaceutical company’s stock after acquiring an additional 25,031 shares during the quarter. Capital International Sarl’s holdings in Pfizer were worth $10,666,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Fiduciary Alliance LLC boosted its stake in shares of Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after purchasing an additional 46,043 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of Pfizer during the third quarter valued at approximately $3,019,000. Money Concepts Capital Corp grew its stake in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after buying an additional 57,188 shares during the last quarter. Vista Investment Partners LLC lifted its stake in shares of Pfizer by 236.1% during the 3rd quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after acquiring an additional 48,900 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. grew its position in Pfizer by 76.4% in the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after acquiring an additional 47,319 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $26.81 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The business has a 50-day simple moving average of $26.34 and a 200-day simple moving average of $25.48. The stock has a market cap of $152.42 billion, a PE ratio of 19.71 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.63 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date was Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research analyst reports. HSBC reiterated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Bank of America dropped their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target for the company. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Monday, March 2nd. Finally, Barclays started coverage on Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.05.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.